Eli Lilly completes small buy of cancer drugmaker — the payoff may come later

Eli Lilly's Point Biopharma acquisition doesn't change our optimism on the diabetes-and-obesity drug giant heading into the new year.

from US Top News and Analysis https://ift.tt/IAF7YCO
https://ift.tt/93XHPWz